ReviewTranslational research : the journal of laboratory and clinical medicine2019
siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.
Review in Translational research : the journal of laboratory and clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 82 citations in OpenAlex.
- Advances in applications of siRNA in cancer therapy: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Breast Cancer Treatments: Drugs Targeting the PI3K/AKT/mTOR Pathway, TNBC Therapy and Future Directions: A Review.Life (Basel, Switzerland) · 2025Review
- Cancer-metastasis-on-a-chip reveals efficacy of bevacizumab and siRNA in overcoming carboplatin resistance in SKOV3 ovarian cancer within a fibrotic metastatic microenvironment.Materials today. Bio · 2025Article
- Expanded insights into the mechanisms of RNA-binding protein regulation of circRNA generation and function in cancer biology and therapy.Genes & diseases · 2025Review
- Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.ACS nano · 2025Article
- TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.Scientific reports · 2025Article
- Compliant immune response of silk-based biomaterials broadens application in wound treatment.Frontiers in pharmacology · 2025Review
- CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent.Frontiers in pharmacology · 2025Review
- Non-coding RNAs as novel biomarkers and therapeutic targets in breast cancer.Oncology reviews · 2025Review
- Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.International journal of molecular sciences · 2024Review
- siRNA-based strategies to combat drug resistance in gastric cancer.Medical oncology (Northwood, London, England) · 2024Review
- Engineered zwitterionic diblock copolymer-siRNA polyplexes provide highly effective treatment of triple-negative breast cancer in a 4T1 murine model.Advanced functional materials · 2024Article
- Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.bioRxiv : the preprint server for biology · 2024Article
- Effects of CD44 siRNA on inhibition, survival, and apoptosis of breast cancer cell lines (MDA-MB-231 and 4T1).Molecular biology reports · 2024Article
- Tumor Cell-Derived Exosomal miR-191-5p Activates M2-Subtype Macrophages Through SOCS3 to Facilitate Breast Cancer.Molecular biotechnology · 2024Article
- Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products.Genes · 2024Review
- Assessment of the Efficacy of the Combination of RNAi of lncRNA DANCR with Chemotherapy to Treat Triple Negative Breast Cancer Using Magnetic Resonance Molecular Imaging.Bioconjugate chemistry · 2024Article
- The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy.Journal of the National Cancer Center · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Small interfering RNA (siRNA) has an established and precise mode of action to achieve protein knockdown. With the ability to target any protein, it is very attractive as a potential therapeutic for a plethora of diseases driven by the (over)expression of certain proteins. Utilizing siRNA to understand and treat cancer, a disease largely driven by genetic aberration, is thus actively investigated. However, the main hurdle for the clinical translation of siRNA therapeutics is to achieve effective delivery of siRNA molecules to tumors and the site of action, the cytosol, within cancer cells. Several nanoparticle delivery platforms for siRNA have been developed. In this Review, we describe recent efforts in developing siRNA therapeutics for the treatment of cancer, with particular emphasis on breast cancer. Instead of conventionally targeting proliferation and apoptosis aspects of tumorigenesis, we focus on recent attempts in targeting cancer's metastasis, drug resistance, and immune evasion, which are considered more challenging and less manageable in clinics with current therapeutic molecules. siRNA can target all proteins, including traditionally undruggable proteins, and is thus poised to address these clinical challenges. Evidence also suggests that siRNA can be superior to antibodies or small molecule inhibitors when inhibiting the same druggable pathway. In addition to cancer cells, the role of the tumor microenvironment has been increasingly appreciated. Components in the tumor microenvironment, particularly immune cells, and thus siRNA-based immunotherapy, are under extensive investigation. Lastly, multiple siRNAs with or without additional drugs can be codelivered on the same nanoparticle to the same target site of action, maximizing their potential synergy while limiting off-target toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.